Cadila Pharmaceuticals
Cadila Pharmaceuticals, also known as Zydus Cadila, is a prominent player in the global pharmaceutical industry, headquartered in Ahmedabad, India. Founded in 1952, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Cadila Pharmaceuticals focuses on research and development, manufacturing, and marketing of a diverse range of pharmaceutical products, including formulations, active pharmaceutical ingredients (APIs), and biotechnology products. With a commitment to innovation, Cadila has achieved significant milestones, such as the development of biosimilars and a robust portfolio of generic medications. The company is recognised for its high-quality standards and has received numerous accolades for its contributions to healthcare. As a leading pharmaceutical manufacturer, Cadila Pharmaceuticals continues to enhance its market position through strategic partnerships and a dedication to improving patient outcomes worldwide.
DitchCarbon Score
How does Cadila Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cadila Pharmaceuticals's score of 0 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cadila Pharmaceuticals's reported carbon emissions
Cadila Pharmaceuticals, headquartered in India, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and reducing their carbon footprints. While Cadila Pharmaceuticals has not disclosed specific commitments or targets, the industry as a whole is moving towards more sustainable practices and emissions reductions. As the company progresses, it may consider establishing measurable targets aligned with global climate goals, which could include commitments to reduce Scope 1, 2, and 3 emissions. This would reflect a proactive approach to environmental responsibility and sustainability in the pharmaceutical sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cadila Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
